Raymond James & Associates’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Raymond James & Associates’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,729	Closed	-$230K	–	3987
2022 Q3	$230K	Sell	8,729 -486	-5%	-$15K	﹤0.01%	3355
2022 Q2	$266K	Sell	9,215 -4,595	-33%	-$137K	﹤0.01%	3307
2022 Q1	$476K	Buy	13,810 +1,225	+10%	+$43.3K	﹤0.01%	3108
2021 Q4	$551K	Buy	+12,585	New	+$596K	﹤0.01%	3012

Other funds holding IDNA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RIG

RiverFront Investment Group Richmond, Virginia $6.46B AUM 18.45% 1-Year Est. Return

Raymond James & Associates's IDNA Position: Q4 2022 in Review

Raymond James & Associates sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q4 2022, closing a stake of 8,729 shares — an estimated $230K sold.

Raymond James & Associates first reported a position in IDNA in Q4 2021 and held it in 4 quarters. The position peaked at $551K in Q4 2021. 75 funds tracked by Wall St. Rank hold IDNA as of Q4 2022.

Raymond James & Associates reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q4 2022 after selling out during the quarter.
Raymond James & Associates sold 8,729 iShares Genomics Immunology and Healthcare ETF shares in Q4 2022, an estimated $230K.
Raymond James & Associates first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 4 quarters.
Raymond James & Associates's iShares Genomics Immunology and Healthcare ETF position peaked at $551K in Q4 2021.
75 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.